Abstract | WHAT IS KNOWN AND OBJECTIVE: METHODS: Clinical trials of telmisartan were identified through electronic searches (MEDLINE, CINAHL, Scopus, and The Cochrane Library) up to and including May 2011. Studies were included if they met the following inclusion criteria: (i) randomized controlled trials that compared telmisartan with other ARBs in hypertensive patients who had insulin resistance or type 2 diabetes mellitus; (ii) using telmisartan as an add-on therapy or a monotherapy for treating hypertension; and (iii) reporting fasting plasma glucose (FPG) and fasting plasma insulin (FPI), or homeostasis model assessment of insulin resistance (HOMA-IR), or adiponectin as an outcome measure. Treatment effect was estimated with the mean difference in the final value of FPG, FPI, HOMA-IR and adiponectin between the telmisartan and the control groups. RESULTS AND DISCUSSION: Eight trials involving a total of 763 patients met the inclusion criteria. Telmisartan was superior to other ARBs in reducing FPG level (mean difference, -8·63 mg/dL; 95% CI -12·29 mg/dL to -4·98 mg/dL; P < 0·00001) and increasing adiponectin level (mean difference, 0·93 μg/dL; 95% CI 0·28 μg/dL to 1·59 μg/dL; P = 0·005). At 80 mg dose, telmisartan may reduce FPI level and HOMA-IR. WHAT IS NEW AND CONCLUSIONS:
|
Authors | N Suksomboon, N Poolsup, T Prasit |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 37
Issue 3
Pg. 319-27
(Jun 2012)
ISSN: 1365-2710 [Electronic] England |
PMID | 21848583
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2011 Blackwell Publishing Ltd. |
Chemical References |
- ADIPOQ protein, human
- Adiponectin
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Benzimidazoles
- Benzoates
- PPAR gamma
- Telmisartan
|
Topics |
- Adiponectin
(blood)
- Angiotensin Receptor Antagonists
(administration & dosage, therapeutic use)
- Antihypertensive Agents
(administration & dosage, therapeutic use)
- Benzimidazoles
(therapeutic use)
- Benzoates
(therapeutic use)
- Diabetes Mellitus, Type 2
(complications)
- Dose-Response Relationship, Drug
- Humans
- Hyperglycemia
(prevention & control)
- Hyperinsulinism
(prevention & control)
- Hypertension
(blood, complications, drug therapy, metabolism)
- Insulin Resistance
- PPAR gamma
(agonists)
- Randomized Controlled Trials as Topic
- Telmisartan
|